Open an account

Pluri

PLUR · NASDAQ

$0.90+$0.0499 (+5.87%)TodayMarket closed ·
Prev close $0.8501

About PLUR

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The company is headquartered in Haifa, Haifa and currently employs 127 full-time employees. The company went IPO on 2007-12-10. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.

Employees
127
Headquarters
Haifa, Haifa
Listed
Dec 10, 2007
Sector
Health Care
Industry
Biotechnology
Website
pluri-biotech.com

PLUR key statistics

Market cap
11.35M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
13.76K
Volume
12.61K
Open price
$0.89
High today
$0.949
Low today
$0.89
52 Week high
$4.87
52 Week low
$0.85

Pluri (PLUR) at a glance

Pluri (PLUR) last traded at $0.90, with a market cap of 11.35M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.89 and $0.949. The current price is 1.1% above the day's low and 5.2% below its high.

Volume so far is 12.61K shares, in line with the average of 13.76K shares a day.

Over the past year Pluri has ranged from $0.85 to $4.87, and now sits 1% of the way up that range.

Pluri met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.71 per share against an estimate of -$0.663.

PLUR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 19.8% on average.

  1. Q1 FY22: reported -$2.88 per share against an estimate of -$3.35
  2. Q2 FY22: reported -$2.72 per share against an estimate of -$3.10
  3. Q3 FY22: reported -$2.48 per share against an estimate of -$2.94
  4. Q4 FY22: reported -$2.24 per share against an estimate of -$2.86
  5. Q1 FY23: reported -$1.52 per share against an estimate of -$2.61
  6. Q4 FY25: reported -$1.00 per share against an estimate of -$0.7446
  7. Q1 FY26: reported -$0.65 per share against an estimate of -$0.7548
  8. Q2 FY26: reported -$0.71 per share against an estimate of -$0.663

PLUR news

  • Press releaseGlobe Newswire

    Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

  • Press releasePRNewswire

    DarioHealth Announces CFO Transition

  • Press releasePRNewswire

    BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Similar companies

Companies in the same industry as Pluri

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.